Because of their involvement in the replicative bypass of DNA adducts formed by genotoxic chemotherapeutics, which promotes drug resistance in cancers [25,26,27,28,29,30,31], TLS DNA polymerases have emerged as promising anti-cancer drug targets [32,33,34,35,36]. Here, FUS is linked to cancer.